News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Optibrium And MolPort Collaborate To Improve Speed And Cost-Efficiency Of Drug Discovery



11/30/2016 10:23:06 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Partnership combines MolPort’s 6.3 Million HTS Compounds with StarDrop’s data analysis and compound design capabilities

CAMBRIDGE, UK and RIGA, LATVIA, 30 November, 2016 – Optibrium™, a developer of software for small molecule design and optimisation, today announced a collaboration with MolPort, the provider of a comprehensive chemicals database, marketplace and order fulfilment platform. The collaboration offers StarDrop™ users fully integrated access to MolPort’s drug discovery database of 6.3 million commercially available screening compounds and chemical building blocks via its curated collection of catalogues from major chemical suppliers. The latest in a series of recent partnerships with commercial providers, this link with MolPort further extends StarDrop’s capabilities to improve the speed, efficiency, and productivity of the drug discovery process.

MolPort specialises in the sourcing, and effective single supplier access, of chemicals for drug discovery. From a collection of curated catalogues from all major suppliers, MolPort has created a marketplace and order fulfilment platform for commercially available chemistries which includes 6.7 million high-throughput screening (HTS) compounds.

StarDrop users can access the MolPort database to quickly search for commercially available screening compounds and reagents. The free link enables users to not only look for exact chemical matches but also select compounds based on similarity to the chemistry of interest. This provides an invaluable tool for chemists to easily enrich their understanding of structure–activity relationships (SAR) in a project’s chemistry. MolPort’s compound search results are presented directly in StarDrop, where its unique capabilities for analysis of SAR and compound optimisation guide the selection of compounds with an improved chance of success.

Dr Matthew Segall, CEO of Optibrium, commented: “We are pleased to be working with MolPort in our latest collaboration with leading providers in drug discovery and wider chemistry fields. MolPort specialises in sourcing large numbers of chemicals from an array of large and the more niche suppliers and StarDrop users can now benefit from seamless access to some 6.3 million screening compounds and building blocks.”

Dr Imants Zudans, CEO of MolPort said: “Over 85% of product inventory listed in the MolPort database is synchronised daily with suppliers. StarDrop users gain direct access to these up-to-date data and can have a very high degree of confidence that all samples can be ordered immediately from MolPort, reducing design-test cycle times.”

For further information on Optibrium and StarDrop, please visit www.optibrium.com/stardrop/stardrop-integration.php or contact info@optibrium.com.

For further information on MolPort, please visit www.molport.com/shop/about-us or contact customerservice@molport.com.

Read at BioSpace.com


comments powered by Disqus
Optibrium
MolPort
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES